Deliverable: Transcripts
Objectives:
n Compare and contrast current treatment options for testosterone replacement therapy (TRT)
n Elicit expert feedback on testosterone undecanoate (Indevus’s Nebido)
n Clarify potential utilization of testosterone undecanoate
Products Highlighted:
n Nebido® (testosterone undecanoate), Indevus
n Testim® (testosterone gel), Auxilium
n Striant® (testosterone buccal system), Columbia Laboratories
n Testoderm® (testosterone trandermal patch), Alza, Johnson & Johnson
n Androderm® (testosterone trandermal patch), Watson Pharmaceuticals
Topics:
n Current TRT treatment practices
n Drivers of therapy/formulation selection
n Strengths and weaknesses of existing agents
n Unmet needs
n Impressions of Nebido efficacy and safety data
n Potential competitors
n Future role of selective androgen receptor modulators (SARMs) in TRT
Selected Quotes:
n In choosing a treatment, variabless that I consider include cost, consistency of treatment, tolerability of treatment, efficacy of treatment and side effects of the various treatment options
n Where cost of the preparation is a primary factor, I first suggest …
n It's an issue for about 30-40% of my patients
n Seeking a well tolerated, affordable option with consistent dosing, and dose flexibility. None of the current options meet all of these needs.
n Depends on dosing freq and stability of T levels between doses. Also depends on how great the rise in Hct will be.
Screening Criteria:
n Board-certified in urology; endocrinology
n 2-30 years of practice
n Significant experience treating hypogonadism with testosterone replacement therapy
n Publication history in hypogonadism
n Clinical trial experience in this domain
Representative Institutions:
n
n Brigham and Women’s Hospital
n
n UCLA
n University Hospitals of
n
| © Panel Intelligence, LLC. 1999-2008. All rights reserved. A wholly owned subsidiary of MCF Corporation (NASDAQ: MERR) Privacy Policy |